Adalimumab

阿达木单抗

Report date: 2026/05/15 20:01:45

Base Information

Drug NameAdalimumab
Drug Alias NameRaheara阿达利单抗Adalimumabum阿达利木单抗阿达莫单抗 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisCoronavirus Disease 2019 (COVID-19)Generalised pustular psoriasis +[40] 
Global Approved IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[7] 
Approved Indications in ChinaArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryUnited States
Original Approved Date2002/12/31
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenWestern UniversityAet BioTech +[15] 
Inactive CompaniesAbbott LaboratoriesOregon Health And Science UniversityWake Forest University +[22] 
Active IndicationsPlaque psoriasisPsoriasisMucopolysaccharidosis VI +[25] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Generalised pustular psoriasisAxial Spondyloarthritis +[15] 

Other Information

ATC CodeL04AB04
Related LinksWikipediaDrugBankKEGG